The gp7O and transmembrane gp2O envelope proteins of simian retrovirus-D serotype 1 (SRV-1) were expressed in Saccharomyces cerevisiae as fusion proteins with human superoxide dismutase (SOD). Expression of the SOD-gp7O and SOD-gp2O sequences yielded fusion proteins of 52 and 29 kilodaltons, respectively. The yeast-expressed SRV-1 envelope proteins were used in an enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies in the sera of rhesus macaques that recovered from SRV-1. Sera from 47 of 49 such monkeys tested positive for antibodies to the SOD-gp7O fusion protein, while 45 of 49 reacted positively to SOD-gp2O. None of 26 SRV-1-nonexposed monkeys tested positive in either ELISA. Monkeys immunized with the recombinant SRV-1 gp2O and gp7O proteins made good ELISA and Western blot (immunoblot) antibodies to whole SRV-1. This antibody was not neutralizing in vitro, however.
SRV-1 gp2O is an envelope transmembrane protein. Genetic and serologic studies indicate that the gp2O protein is more conserved among the various type D retroviruses than is the gp7O protein (15, 33, 35) .
SRV-1 is the only retrovirus for which a highly efficacious vaccine has been developed (29) . Protective immunity, associated with high titers of virus-neutralizing antibodies, has been induced in adolescent rhesus monkeys with a Formalininactivated whole-virus vaccine. Adolescent rhesus monkeys immunized with this vaccine were totally protected against a lethal challenge exposure with virulent SRV-1 (29) . The fact that rhesus monkeys can be protected against SRV-1 infection with whole-virus vaccine makes this virushost system one model for more modem retroviral vaccine strategies. A particularly attractive vaccine strategy would be to produce the envelope proteins in an appropriate yeast, bacterial, mammalian cell, or vaccinia virus expression system.
We describe in this report the expression of SRV-1 gp2O and gp7O proteins in Saccharomyces cerevisiae and their subsequent purification from yeast cell lysates. The proteins were expressed in large amounts, appeared to be recognized to high titer by sera from SRV-1-immune rhesus macaques, and were immunogenic in monkeys.
MATERIALS AND METHODS
Virus preparation. SRV-1 adapted to grow in human T-lymphoblastoid cells (HUT-78) was purified by procedures that have been previously reported (24) .
Monoclonal antibodies. A mouse monoclonal antibody to SRV-1 gp2O was produced by standard procedures. The characterization of this monoclonal antibody has been recently reported (24) .
ELISA. Enzyme-linked immunosorbent assay (ELISA) for the detection of serum antibodies to whole SRV-1 has been previously described (24, 28) . ELISAs for antibodies to SRV-1 gp2O and gp7O yeast-expressed proteins were con-SRV-1 ENVELOPE GLYCOPROTEINS 1775 ducted by previously reported procedures (3, 36) . The concentration of yeast-expressed protein used to coat ELISA wells was 4 jig/ml.
PAGE. Polyacrylamide gel electrophoresis (PAGE) was conducted as originally described by Laemmli (25) . Standard proteins (Bethesda Research Laboratories, Inc., Gaithersburg, Md.) were used for molecular weight markers. Protein concentrations were measured by the procedure of Bradford (8) .
Western blotting. Proteins were separated by sodium dodecyl sulfate (SDS)-PAGE and transferred to nitrocellulose paper (Schleicher & Schuell, Inc., Keene, N.H.) essentially as described by Burnett (9) . After the proteins were transferred, the nitrocellulose papers were incubated with phosphate-buffered saline, pH 7.4, containing 1% nonfat dry milk to prevent nonspecific protein binding. Monkey sera to be tested were diluted 1:100 in the same buffer, placed in a test tube with the nitrocellulose paper strip, and incubated at room temperature for 1 h. After being washed (in phosphatebuffered saline), the strips were treated for 1 h at room temperature with goat anti-rhesus immunoglobulin G conjugated to horseradish peroxidase (Orgamon Teknika, Malvemn, Pa.). The labeled antiserum was diluted 1:500 with phosphate-buffered saline. After being washed, the strips were reacted with a substrate solution containing 25 mg of diaminobenzidine (Sigma Chemical Co., St. Louis, Mo.) and 15 ,ul of 30% H202 in 50 ml of 0.1 M Tris hydrochloride buffer, pH 7.5. Protein bands were visualized in 3 to 5 min.
Monkey sera. The sera used in this study were from rhesus macaques that had recovered from natural or experimental SRV-1 infection or had never been exposed to the virus (antibody negative, virus negative) (24) . The panel of sera contained 49 sera that were antibody positive by whole-SRV-1 ELISA and 26 sera that were negative.
Yeast strains and media. S. cerevisiae 2150, constructed by Chiron Laboratories, Emeryville, Calif., was used for these studies (35) . Recombinant plasmids were propagated in Escherichia coli HB101. Luria broth (30) and Luria agar (1.5% agar in Luria broth) were used for growth media. Both broth and agar media contained 50 ,ug of ampicillin per ml. Transformed yeast cells were propagated in leucine-deficient media containing 8% glucose at 30°C with continuous aeration. Protein synthesis was induced by growth in YEP (1% [wt/vol] yeast extract, 2% peptone broth) containing 2.5% ethanol.
Plasmids. Procedures for purifying plasmid DNA have been previously described (5) . Plasmid pUC19/SRV-1, which carried the permuted BamHI fragment containing the entire SRV-1 genome, was the basis for further constructs (33) . Plasmid pUC18hr/SRV-1 carried the EcoRI (at nucleotide position 5391)-HindlIl (at position 7505) fragment of the SRV-1 genome. This 2,115-base-pair fragment contained the entire coding region for SRV-1 gp7O and gp2O and part of the SRV-1 polymerase.
Plasmid pBS24 was a yeast expression vector derived from the pAB24 plasmid. The pBS24 plasmid combined a desirable E. coli replication origin, an ampicillin resistance (Amp') gene, a 2,um yeast replication origin, and the LEU2-d and URA3 yeast genetic markers (3) .
DNA manipulation. Conditions for DNA phosphorylation, restriction enzyme digestions, and ligation have been previously described (26) . Plasmid DNA was purified by minilysate (23) (18) . Heterologous genes cloned into such a vector are often expressed at a similar high level.
Bacterial and yeast transformations. Transformation of S. cerevisiae 2150 was performed by the procedures of Hinnen and co-workers (20) . Bacterial transformation was done by the CaCl2 procedure (12) , and plasmid preparations from the candidate bacterial colonies were analyzed on 1% agarose or 7% acrylamide gels.
Preparation of yeast cell extracts and total cell lysates. Yeast strains that expressed the appropriate fusion proteins were grown to the desired cell density at 30°C in 1 liter of medium as described previously (3) . Yeast cells were isolated by centrifugation at 4,000 x g for 10 min. Yeast pellets were washed once with phosphate-buffered saline and suspended in 25 Purification of SOD-gp2O and SOD-gp7O polypeptides. The SOD-gp2O fusion protein was precipitated from the supernatant of the yeast cell lysate with 40% (vol/vol) saturated ammonium sulfate. The precipitate was harvested by centrifugation and suspended and dialyzed overnight in 0.1 M Tris buffer (pH 8.0).
The semipurified SOD-gp2O protein was further purified by immunosorbent affinity column chromatography by using SRV-1 gp2O mouse monoclonal immunoglobulin G purified from ascites fluid by 40% (vol/vol) saturated ammonium sulfate precipitation. Two grams of cyanogen bromide-activated Sepharose 4B (Pharmacia, Inc., Piscataway, N.J.) was washed as directed by the manufacturer and reacted with 20 mg of the purified immunoglobulin G. After blocking of unreacted sites with 0.2 M glycine (pH 8.0), the column was preeluted with 0.2 M glycine buffer (pH 2.0). The column was then equilibrated with 0.1 M Tris (pH 8.0). Semipurified yeast extracts containing SOD-gp2O were equilibrated in 0.1 M Tris (pH 8.0) and passed over the column. After being washed, the antibody-bound SOD-gp2O was eluted with 0.2 M glycine (pH 2.0). The purified protein was pooled, desalted, concentrated, and used in subsequent experiments.
Extraction of SOD-gp7O from the pelleted material resulting from cell lysis required four extraction steps with different buffers. Unless stated otherwise, all subsequent purification steps were performed at 4°C and centrifugation was at 100,000 x g for 20 min. In step 1, the pellet resulting from 8 .0], 10 mM EDTA, 1 mM phenylmethylsulfonyl fluoride) at room temperature for 5 min. The suspension was centrifuged, and the supernatant was saved (designated the S-1 fraction). In step 2, the pellet was further extracted with 6 M urea buffer and centrifuged (the supernatant was designated fraction S-2).
Step 3 was a repeat of step 2 (the supernatant fraction was designated S-3). The remaining pellet was extracted with SDS loading buffer (10% glycerol, 50 mM dithiothreitol, 3% SDS, 0.0625 M Tris hydrochloride [pH 6.8], 0.02% bromphenol blue). The supernatant fraction was designated S-4.
SOD-gp7O was finally purified by electroelution from SDS-PAGE. After electrophoresis, the fusion protein was visualized by staining with Coomassie blue and sliced from the gel. After electroelution, the sample within the collection well was lyophilized. A single protein band was visualized on PAGE. The protein also reacted strongly in Western blots treated with monkey antiserum containing a high titer of SRV-1 gp7O antibody. The electroeluted protein was then subjected to the pico:TAG system (Waters Associates, Inc., Milford, Mass.) for analysis of amino acid composition as previously described (4, 22) .
Animal immunization. Four adolescent rhesus macaques were obtained from the California Primate Research Center, University of California, Davis, and housed in their facilities. Two animals were inoculated with the SRV-1 gp2O recombinant protein, and two were inoculated with the recombinant SRV-1 gp7O protein. The immunizing dose was 150 mg of purified protein in threonyl muramyl-dipeptide adjuvant (29) . The preparation was given intramuscularly three times at 3 to 4-week intervals.
Virus-neutralizing antibody. Virus-neutralizing antibodies were measured in vitro by a syncytium inhibition assay (29) . RESULTS
Construction of SRV-1 gp2O and gp7O expression plasmids. A PstI-TaqI fragment of SRV-1 cDNA corresponding to the gp2O coding region (nucleotides 7086 to 7392) of the SRV-1 genome was excised from the cloned proviral plasmid pUC19/SRV-1. The excised fragment encoded a protein comprising alanine 16 through isoleucine 117 of SRV-1 gp2O. Hydrophilicity and hydrophobicity analyses (data not shown) of the amino acid sequence indicated that this portion of SRV-1 gp2O was hydrophilic and most likely represented the external SRV-1 gp7O-anchoring domain (Fig.  1A) . The fragment was expanded with an Ncol linker at the 5' end and a Sall linker at the 3' end. The final gene fragment comprised nucleotides at position 7076 at the 5' end and position 7408 at the 3' end.
A 936-base-pair AccI fragment corresponding to the SRV-1 gp7O-coding region extending from nucleotides 6094 to 7029 of the SRV-1 genome was isolated from plasmid pUC18hr/SRV-1. The flanking regions of the AccI fragment were ligated with Ncol-Sall synthetic linkers and included nucleotides at position 6065 at the 5' end and position 7042 at the 3' end.
The NcoI-SaiI fragments were cloned into a yeast expression vector containing the human SOD gene under control of the ADH-2:GAPDH hybrid promoter. DNA fragments for the heterologous gene products were cloned into a polylinker containing NcoI and Sall restriction enzyme sites situated at the stop codon for SOD. The structures of the final expression plasmids are illustrated in Fig. 1B .
The pBS24-ADH-2:GAPDH-SOD-gp2O expression vector directed the synthesis of a fusion protein containing 111 The recombinant plasmids were propagated in E. coli HB101 and used to transform S. cerevisiae 2150. S. cerevisiae containing the recombinant plasmids was selected on Leu+ medium. Single-transformant colonies, which harbored the pBS24-ADH-2:GAPDH-SOD-gp7O or pBS24-ADH-2:GAP DH-SOD-gp2O plasmid, were grown in high-glucose (8%) medium and then induced in YEP medium containing 2.5% ethanol. The yeast expression vectors directed the expression of the SOD-gp2O or SOD-70 fusion protein, with SOD at the N terminus and gp2O or gp7O at the C terminus.
When the gp2O and SOD sequences were in the same reading frames, the theoretical polypeptide product was a 29-kilodalton (kDa) protein. This molecular mass was calcu-lated from the sum of the SOD (17 kDa) and gp20 (12 kDa) sequences inserted into the expression vector. As predicted, cell lysates from S. cerevisiae containing the appropriate plasmid yielded a protein of 29 kDa when analyzed by SDS-PAGE and stained with Coomassie brilliant blue (Fig.  2) . The resulting SOD-gp70 fusion protein had a theoretical molecular mass of 52 kDa based on the sum of SOD (17 kDa) and gp70 (35 kDa) encoded by the expression vector. Yeast lysates containing the expressed SOD-gp70 protein contained a new protein band of 52 kDa when analyzed by SDS-PAGE (Fig. 2) . Extracts of control yeast cells carrying only the vector plasmid pBS24 did not contain new 29-or 52-kDa bands (Fig. 2) . The SOD-gp2O and SOD-gp70 fusion proteins were stable in S. cerevisiae and were produced at levels of up to 5% of the total yeast cell proteins.
Characterization of SOD-gp2O and SOD-gp7O polypeptides. The SOD-gp20 and SOD-gp70 proteins produced in S. cerevisiae were tested for immunogenicity by (i) their reaction with appropriate antibodies in Western blots and (ii) elimination of the possibility that the antisera recognized the SOD moiety and not the gp 20 or gp70 moiety.
Yeast cell extracts containing the recombinant proteins, normal yeast cell lysates, and purified SOD were tested by Western immunoblotting. Prominent bands at 29 kDa (SODgp20) or 52 kDa (SOD-gp70) were seen in Western blots of the respective proteins reacted with SRV-1 immune monkey serum but not in those reacted with serum from a norml animal (Fig. 3) . The immune and nonimmune monkey sera did not react with any antigens in normal yeast cell lysates or purified SOD (Fig. 3) . Western blot strips of the two recombinant proteins, normal yeast cell lysates, and SOD were also reacted with a mouse monoclonal antibody against SRV-1 gp2O. Only the Western blot made from SOD-gp20 reacted with the monoclonal antibody (Fig. 3) . A rabbit antiserum to purified SOD identified a 29-kDa band on the Western blot of SOD-gp2O, a 52-kDa band on the SOD-gp 70 1 blot, and a 17-kDa band on the SOD blot (Fig. 3) . The antiserum failed to recognize any protein bands on the Western blot of the control yeast cell lysate (Fig. 3) . Since we did not have a monoclonal antibody against the SRV-1 gp70 protein, the identity of the gp70 portion of the SODgp7O fusion was reconfirmed by amino acid analysis. The polar amino acid and methionine contents of the SOD-gp70 protein were identical to the predicted polar amino acid and methionine compositions of SRV-1 gp7O deduced from the SRV-1 genome sequence (33) (data not shown).
Purification of SOD-gp2O. After lysis of S. cerevisiae, the SOD-gp2O-containing supernatant was precipitated with 40% (vol/vol) saturated ammonium sulfate. The fusion protein was enriched by this treatment (Fig. 2) . The enriched SODgp20 fusion protein was then loaded onto an immunoaffinity column coated with mouse monoclonal immunoglobulin G against SRV-1 gp20. The SOD-gp2O protein that was eluted from the column with 0.2 M glycine (pH 2.0) was about 95% pure as determined by PAGE analysis (Fig. 2) .
Purification of SOD-gp7O. Yeast extracts were prepared as described in Materials and Methods. The protein fractions from the various stages of purification (S-1 through S-4) were separated by SDS-PAGE, and the polypeptide bands were stained with Coomassie brilliant blue. The SOD-gp70 fusion protein remained insoluble after disruption in S. cerevisiae and was partially purified by subsequent urea extractions. Figure 2 shows a Coomassie brilliant blue-stained gel of yeast cell extracts collected at each of the four extraction steps. This analysis suggested that the second 6 M urea extract was greater than 90% pure. Detection of SRV-1 gp2O antibodies in monkey sera by ELISA with SOD-gp2O fusion protein. SOD-gp2O that had been purified by immunoaffinity column chromatography was diluted in ELISA coating buffer and bound to microtiter plates (0.4 ,ug/100 ,ul per well). We tested 49 SRV-1 antibodypositive (by whole-virus ELISA) and 26 SRV-1 antibodynegative sera in the SOD-gp2O ELISA. All sera were screened at a dilution of 1:100. Of 49 sera that reacted positively to whole SDS-disrupted SRV-1 in ELISA, 45 also reacted positively in the SOD-gp2O ELISA ( Table 1 ). The 26 SRV-1 antibody-negative sera all tested negative. Serum with high ELISA readings for antibodies to whole SRV-1 also gave high optical density readings for antibodies to SOD-gp2O. There were four serum samples that scored positive in the whole-SRV-1 ELISA but were not detected by the SODgp2O ELISA. All four of these sera were tested on Western blots made from whole SRV-1. Three of the sera reacted only with the major core protein (p27) of SRV-1, while one serum reacted only with p31 (data not shown).
Detection of SRV-1 gp7O antibodies in monkey sera by ELISA with the SOD-gp7O fusion protein. The SOD-gp7O ELISA was conducted in the same way as the SOD-gp2O ELISA. Microtiter plates were coated with 100 ,ul of 6 M urea-extracted SOD-gp7O containing 4 ,ug of protein per ml. Of 49 monkey sera that reacted to whole SRV-1 in ELISA, 47 recognized the recombinant gp7O ( Table 1) . None of the SRV-1-negative sera reacted in the SOD-gp7O ELISA. The 47 SOD-gp7O-positive sera were all tested by Western blotting. Only samples that had optical density readings of >0.400 (25 of 47 sera) on the SOD-gp7O ELISA recognized SRV-1 gp7O in Western blots. The 22 sera that had optical density readings of 0.10 to 0.32 all tested negative in Western blots. Unlike the SOD-gp2O assay, which had the same sensitivity as Western blotting, the SOD-gp7O ELISA appeared to be more sensitive in detecting its corresponding antibodies.
To verify that there was a quantitative difference in the amount of SRV-1 gp7O antibodies present in monkey sera that tested strongly or weakly in the SOD-gp7O ELISA, a number of the sera were titrated to endpoint. Monkey sera containing SRV-1 gp7O antibodies detectable on Western blots had endpoint titers ranging from 1:400 to 1:1,600 in the SOD-gp7O ELISA. Sera with endpoint titers below 1:400 failed to react with SRV-1 gp7O on Western blots. Figure 4 shows the titration curves of strong, weak, and negative antisera to SRV-1 gp7O in the single-dilution ELISA.
Immunogenicity of SOD-gp2O ad SOD-gp7O proteins. Two adolescent rhesus macaques were immunized with purified SOD-gp2O, and two were immunized with purified SODgp7O. No antibodies to the native proteins were detected by Western blotting after the first immunization. Weak bands were seen in Western blots after the second immunization, and strong bands were seen after the third (Fig. 5 ). Wholevirus ELISA antibodies were also detected after the third immunization in all four animals. The monkeys that received the SOD-gp2O protein both had titers of 1:100, and those immunized with SOD-gp7O had titers of 1:100 and 1:300. No virus-neutralizing activity was detected in sera collected from the four animals after their third immunization. No further increase in antibodies to whole SRV-1 occurred in ELISA or Western blots after a fourth immunization. DISCUSSION Numerous different immunologically and biologically active polypeptides have been expressed in the yeast S. cerevisiae. These include hepatitis B virus surface antigen (38) , human alpha interferon (14) , and human immunodeficiency virus envelope and reverse transcriptase enzymes (1) (2) (3) . This system also proved highly effective in our hands for expression of both the exterior and transmembrane envelope proteins of a group D simian retrovirus. Although the SRV-1 envelope proteins that we expressed were not glycosylated, they nevertheless were highly immunogenic in both ELISAs and Western blot assays against SRV-1-immune monkey sera.
The yeast-expressed SOD-gp20 and SOD-gp7O fusion proteins were used for antibody detection in SRV-1-immune rhesus monkeys. Immunity to the infection is more likely to occur in animals that are older at the time of natural or experimental exposure (25a) or younger rhesus monkeys that have been vaccinated with a whole-SRV-1 vaccine (29) . Monkeys that fail to recover from the initial infection become persistently viremic. Persistently viremic rhesus monkeys either die of an acquired immunodeficiencylike syndrome or become asymptomatic carriers for life (24, 25a) . SRV-1-immune rhesus monkeys had high antibody titers to SOD-gp2O and SOD-gp70, indicating that immunologically relevant antigenic epitopes were still present on the yeastexpressed proteins. These findings indicated that recombinant proteins can be used interchangeably with whole SRV-1 in antibody detection ELISAs. The fact that none of the 49 monkey sera reacted against the SOD moiety of the fusion protein indicates that separation of SOD from yeast-expressed gp7O or gp2O protein is not necessary.
Monkeys immunized with small amounts of SRV-1 gp2O or gp7O yeast-derived protein made good levels of antibodies after three immunizations. Although these antibodies reacted well with whole SRV-1 in ELISAs and Western blots, they did not neutralize SRV-1 in vitro. The failure of the monkeys immunized with the gp7O preparation to produce virus-neutralizing antibody was troubling. Over 80% of the amino acid backbone of the native envelope protein was expressed by S. cerevisiae, and it seemed to be recognized very efficiently by animals that recovered from SRV-1 infection. Either the remaining 20% of the protein contains important epitopes for neutralizing activity or glycosylation and tertiary structure are more important than originally thought. It is also possible that the titer of SOD-gp70 antibodies must be higher before neutralization occurs. Monkeys immunized with the proteins had antibody titers to whole SRV-1 in ELISA on the order of 1:100 to 1:300. These titers were considerably below the 1:400-to-1:1,600 titers measured in sera from monkeys that recovered from SRV-1 infection.
